Notice · For research and educational reference. Not medical advice. Intended for licensed professionals. Nothing on this site is offered for sale other than informational access.

All Info Peptides
All monographs

Metabolic & Incretin

Cagrilintide

Also known as · AM833

Overview

A long-acting amylin analogue investigated alone and in fixed-ratio combination with semaglutide (CagriSema) for weight management. Acts on satiety pathways distinct from incretin signaling.

Research profile · for clinicians

Based on research: an amylin analogue studied as a satiety agent that works through a different pathway than incretins. Trials most often pair it with semaglutide (CagriSema) to combine hindbrain satiety signaling with GLP-1 mechanisms for additive weight-management effects.

Mechanism of action

Activation of amylin and calcitonin receptors in the area postrema and hindbrain delays gastric emptying and amplifies satiety signaling, complementary to GLP-1 mechanisms.

Research record

  • [01]Phase II monotherapy and CagriSema combination obesity trials.
  • [02]REDEFINE Phase III program in obesity and T2D.

Selected references

  • Cagrilintide and semaglutide combination in obesity

    Lancet, 2021